Next Oncology

Austin, Texas 78758

5 studies enrolling now · 30 studies all time

What they study most

Advanced Breast Cancer, Advanced Cancer, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Ovarian Carcinoma, Advanced Solid Malignancies, Advanced Solid Tumor, Advanced Solid Tumor or Lymphoma, Advanced Solid Tumors, Appendix Cancer, BRAF Gene Mutation, Biliary Cancer Metastatic

Studies at this site

• A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors — Recruiting now
• A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors — Recruiting now
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations — Recruiting now
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors — Recruiting now
• Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors — Recruiting now
• PAS-004 in Patients With Advanced Solid Tumors — Recruiting now
• Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer — Stopped early
• Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors — Completed
• Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors — Completed
• Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors — Completed
• S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP — Running, not enrolling
• Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors — Completed
• Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) — Running, not enrolling
• Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors — Stopped early
• A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors — Stopped early
• A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). — Stopped early
• A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors — Running, not enrolling
• A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors — Running, not enrolling
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies — Stopped early
• Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy — Completed
• Study of IK-595 in RAS- or RAF-altered Advanced Tumors — Stopped early
• A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. — Stopped early
• Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer — Completed
• A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer — Paused
• A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer — Status unconfirmed
• Study of ASN004 in Patients With Advanced Solid Tumors — Completed
• PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates — Completed
• A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors — Completed
• A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma — Status unconfirmed
• Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies — Stopped early